Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SSGJ-716 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SSGJ-716 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| SSGJ-716 | DRUG | Single and multiple subcutaneous injection |
| Placebo | DRUG | Single and multiple subcutaneous injection |
Inclusion Criteria: * Able to understand protocol requirements and sign a written ICF. * Male or female subjects aged 18-45 years when signing the ICF. * Male subjects with body weight ≥ 50 kg, and female subjects with body weight ≥ 45 kg. Subjects with BMI between 18 and 28 kg/m2. * Subjects whose...
SSGJ-716 is an investigational small molecule being developed for the treatment of atopic dermatitis (AD). It is currently in Phase 1 clinical development, with a study evaluating its safety and tolerability in healthy adults and participants with moderate-to-severe atopic dermatitis.
SSGJ-716 is being developed by Sunshine Biopharma Inc., a company listed on the stock exchange under the ticker SBFM. The company is conducting a Phase 1 clinical trial of SSGJ-716 in China.
SSGJ-716 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study is currently recruiting participants to evaluate the drug in healthy adults and those with moderate-to-severe atopic dermatitis.
SSGJ-716 is being studied in a Phase 1 clinical trial registered as NCT07693738. This randomized, double-blind, placebo-controlled study is recruiting 96 participants in China, including healthy adults and individuals with moderate-to-severe atopic dermatitis.
SSGJ-716 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The ongoing trial is designed to assess its safety and tolerability, and further studies would be needed before any regulatory approval could be considered.